July 1, 2009 1:17 PM
- Text
Cephalon's Nuvigil Test Included "Vacation" in France
(MoneyWatch) Cephalon will ask the FDA to approve its sleep drug Nuvigil for "Eastbound" jet lag. Not Westbound. Eastbound, the company says.
Why such a strange indication? Turns out Cephalon put 427 adults through what has to be the best clinical trial ever: They flew them from the East Coast of the U.S. to France for a drug-filled vacation observation. Regs chief Lesley Russell told investors:
Cepahlon's launch of Nuvigil is expected any day now; the drug is expected to replace Provigil which is beset by generic patent challenges. CEO Frank Baldino had this to say about his strategy in his Q1 call:
Hat tip to Internet Drug News
Subjects were flown from the East Coast of the United States through six hours of time zone changes to arrive in France early in the morning, where they were escorted to a sleep center. Subjects were then given NUVIGIL or placebo once a day for three days. ... Patients taking 150-milligram dose of NUVIGIL showed a statistically significant improvement over placebo.BNET readers know that this is not the first novel testing method Cephalon has used. You can read about the cocaine-addicted-monkeys chapter of Cepahlon's history here.
Cepahlon's launch of Nuvigil is expected any day now; the drug is expected to replace Provigil which is beset by generic patent challenges. CEO Frank Baldino had this to say about his strategy in his Q1 call:
We're particularly pleased to offer NUVIGIL at a discount to PROVIGIL.It's the height of chutzpah. The reason Nuvigil will be offered at a "discount" to Provigil is because Cephalon has deliberately raised the price of Provigil in order to make Nuvigil look like a bargain by comparison.
Hat tip to Internet Drug News
- See previous BNET coverage of Cephalon and Provigil:
- The FTC's Pay-for-Delay Threat: It's All Cephalon CEO Baldino's Fault
- Is Cephalon's Provigil Addictive? Ask the Cocaine-Using Monkeys It Was Tested On.
- List of 56 Drugs That Should Not Be Mixed With Viagra Contains Some Surprises
- Cephalon: Damn the Torpedoes! We're Raising Prices!
- "Pain Is Pain": Cephalon's Marketing Comes Under DOJ Control
- Behind Cephalon's Numbers: a Big Cancer Bet and Signs of Skepticism
- Insomnia Pill Makers Go After Elderly With New 'Fear of Falling'
- FTC accuses Cephalon over Provigil in patent case
Latest Now in MoneyWatch
- States, Feds to announce new mortgage settlement
- Management changes at Ford
- Unemployment aid applications near a 4-year low
- PepsiCo's net rises; plans to cut 8,700 jobs
- Smartr: A brilliant contacts app for smartphones
- What happens if your insurance company fails?
- Student loan debt: the next financial disaster?
- Investing: Four words that can rob you blind
- How to get the fastest tax refund
- 10 employee types that drive managers crazy
- How leaders know it's time to quit
- Greece fails to agree terms with EU creditors
- 5 banks in $26B settlement with feds over abuses
- Gas prices continue to creep up
- Joe Coffee | Secrets of Successful Startups
- Small business mistake: coasting on past success
- Groupon's revenue, losses grow quarter to quarter
Latest CBS News Headlines
on Facebook
on CBS News
- UVa. case prosecutors: Huguely sent death threat
- India's global pharmacy role threatened by EU pact
- APNewsBreak: Snyder ties school funding to scores
- Summary Box: Lenovo 3Q profit up, warns on disks
on Facebook
- Calif. surfer runs fastest-growing camera company
- Mo. teen gets life in prison for murder of 9-year-old girl
- "Person to Person": Bon Jovi behind the scenes
- Adele opens up about vocal cord surgery
on CBS News






